Health Ministry proposes immediate licence suspension for substandard drugs

In a major push to overhaul drug safety regulations, the Union Ministry of Health and Family Welfare has proposed strict amendments to the Drugs Rules, 1945. The draft rules will mandate the immediate suspension of manufacturing licences for of drugs declared Not of Standard Quality (NSQ) on key quality parameters, eliminating regulatory delays that previously allowed non-compliant batches to stay on hospital and pharmacy shelves.

Under current provisions, revoking or suspending a drug manufacturing licence requires lengthy administrative procedures, including mandatory show-cause notices. This statutory time lag often leaves defective drugs in circulation.

Also read | Lilly’s retatrutide outperforms Ozempic on weight loss in diabetes trial; safety concerns remain

The proposed amendments empower the Central Licensing Approving Authority and State Licensing Authorities to immediately halt manufacturing upon receiving a Government Analyst report declaring a drug NSQ.

Explaining the rationale, the official release notes, "Under the existing provisions of the Drugs Rules, 1945, suspension or cancellation of a manufacturing licence is preceded by the prescribed regulatory procedure, including issuance of a show-cause notice. This may result in a time gap between the declaration of a drug as NSQ and initiation of regulatory action. During this period, the concerned drug may continue to remain in circulation, posing potential risks to public health and making effective recall more challenging."

Five core parameters

The stringent swift-suspension rule specifically targets five non-negotiable parameters vital to medicine efficacy: assay, dissolution, related substances, impurities, and sterility.

Failure to meet any of these criteria will halt production instantly until comprehensive corrective protocols are met. Addressing the safety mandate, the ministry emphasized that "the proposed amendments seek to enable prompt regulatory intervention upon detection of substandard medicines, prevent their continued manufacture and distribution, and strengthen the mechanism for ensuring compliance with prescribed quality standards, in the interest of patient safety and public health."

Also read | Sun Pharma's ILUMYA gets US nod for psoriatic arthritis: What patients need to know

Suspended licences will not be restored automatically. Reinstatement will require manufacturers to perform a formal Root Cause Analysis (RCA) and implement a verified Corrective and Preventive Action (CAPA) plan, subject to on-site validation by licensing authorities.

To prevent coordination lapses across state borders, amendments to Form 13 mandate that Government Analyst test reports be endorsed simultaneously to the Drugs Controller General of India (DCGI), state licensing authorities, manufacturers, and marketers.

Rising cost of non-compliance

For pharmaceutical manufacturers and contract marketers, the proposed amendments shift accountability from retroactive explanation to absolute compliance. Companies can no longer count on extended legal buffers to clear existing stock while answering regulatory notices.

Pharma units will need to tighten in-house quality assurance, raw material sourcing, and batch testing to prevent sudden operational shutdowns. Contract manufacturers and brand marketers will also share simultaneous risk, driving higher quality governance across the entire supply chain.

For healthcare providers and patients, the draft notification offers strong structural protection against ineffective or contaminated formulations. Halting production at the test report stage prevents flawed batches from reaching retail counters.

Simultaneous reporting to national regulators and state inspectors ensures swift market recalls, reinforcing confidence in the safety and therapeutic reliability of medicines manufactured nationwide. The draft rules will remain open for public feedback for 30 days.